Drugs / Flu D-QIV
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05047770 | Oct 2021 → Aug 2022 | herpes zoster | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flu D-QIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05047770 ↗ |
| Modality | Vaccine | “The objective of the study was to assess the safety and immunogenicity of mRNA-1273 COVID-19 booster vaccination when co-administered with an egg-based standard dose seasonal...” PMID 38513689 ↗ Mar 2024 |
| Route | Intramuscular | “1 dose of Flu D-QIV vaccine administered intramuscularly, either sequentially (FluD-QIVSeq Group) or simultaneously (FluD-QIVCoAd Group) with the mRNA-1273 booster dose.” NCT05047770 ↗ |